
Anastasia Bougea

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8620523/publications.pdf Version: 2024-02-01



ANASTASIA ROUCEA

#	Article	IF	CITATIONS
1	Mediterranean diet and cognitive health: Initial results from the Hellenic Longitudinal Investigation of Ageing and Diet. PLoS ONE, 2017, 12, e0182048.	1.1	218
2	CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. Journal of the Neurological Sciences, 2017, 382, 91-95.	0.3	66
3	Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. Neurological Sciences, 2019, 40, 929-938.	0.9	59
4	A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease. Movement Disorders, 2021, 36, 1624-1633.	2.2	54
5	Laryngopharyngeal reflux disease in the Greek general population, prevalence and risk factors. BMC Ear, Nose and Throat Disorders, 2015, 15, 7.	2.6	48
6	Circulating Brainâ€Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease. Movement Disorders, 2020, 35, 457-467.	2.2	43
7	Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Spectrum Disorders. Dementia and Geriatric Cognitive Disorders, 2017, 44, 144-152.	0.7	42
8	Differentially Expressed Circular <scp>RNAs</scp> in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease. Movement Disorders, 2021, 36, 1170-1179.	2.2	38
9	Validation of differentially expressed brainâ€enriched microRNAs in the plasma of PD patients. Annals of Clinical and Translational Neurology, 2020, 7, 1594-1607.	1.7	36
10	Salivary alpha-synuclein as a biomarker for Parkinson's disease: a systematic review. Journal of Neural Transmission, 2019, 126, 1373-1382.	1.4	34
11	Higher probability of prodromal Parkinson disease is related to lower cognitive performance. Neurology, 2019, 92, e2261-e2272.	1.5	34
12	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.4	33
13	Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2016, 55, 1453-1461.	1.2	30
14	Melatonin 4 mg as prophylactic therapy for primary headaches: a pilot study. Functional Neurology, 2016, 31, 33-7.	1.3	29
15	Reliability and Validation of the Greek Version of the Boston Carpal Tunnel Questionnaire. Hand, 2018, 13, 593-599.	0.7	28
16	A Systematic Review of Peripheral and Central Nervous System Involvement of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome, and Associated Immunological Profiles. International Journal of Chronic Diseases, 2015, 2015, 1-11.	1.9	27
17	Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. Parkinsonism and Related Disorders, 2017, 35, 82-87.	1.1	27
18	Optimal treatment of HIV-associated neurocognitive disorders: myths and reality. A critical review. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611983822.	1.1	24

ANASTASIA BOUGEA

#	Article	IF	CITATIONS
19	Relationship of Migraine and Tensionâ€Type Headache With Hypothyroidism: A Literature Review. Headache, 2019, 59, 1174-1186.	1.8	23
20	Stress management for headaches in children and adolescents: A review and practical recommendations for health promotion programs and well-being. Journal of Child Health Care, 2018, 22, 19-33.	0.7	21
21	Proton Pump Inhibitors for the Treatment of Laryngopharyngeal Reflux. A Systematic Review. Journal of Voice, 2020, 34, 918-929.	0.6	21
22	Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease. Journal of Neurology, 2018, 265, 2295-2301.	1.8	20
23	Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study. Neurological Sciences, 2020, 41, 877-884.	0.9	19
24	Massage therapy as a complementary treatment for Parkinson's disease: A Systematic Literature Review. Complementary Therapies in Medicine, 2020, 49, 102340.	1.3	19
25	Medical cannabis as an alternative therapeutics for Parkinsons' disease: Systematic review. Complementary Therapies in Clinical Practice, 2020, 39, 101154.	0.7	19
26	The first Greek case of heterozygous cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy: An atypical clinico-radiological presentation. Neuroradiology Journal, 2017, 30, 583-585.	0.6	17
27	An update of neurological manifestations of vasculitides and connective tissue diseases: a literature review. Einstein (Sao Paulo, Brazil), 2015, 13, 627-635.	0.3	16
28	New markers in Parkinson's disease. Advances in Clinical Chemistry, 2020, 96, 137-178.	1.8	16
29	Psychosocial and Trauma-Related Stress and Risk of Dementia: A Meta-Analytic Systematic Review of Longitudinal Studies. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 24-37.	1.2	15
30	An Age-Related Morphometric Profile of Skeletal Muscle in Healthy Untrained Women. Journal of Clinical Medicine, 2016, 5, 97.	1.0	13
31	Inhaled Corticosteroids and Voice Problems. What Is New?. Journal of Voice, 2017, 31, 384.e1-384.e7.	0.6	13
32	Levodopa-induced skin disorders in patients with Parkinson disease: a systematic literature review approach. Acta Neurologica Belgica, 2019, 119, 325-336.	0.5	13
33	High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases. Journal of Neural Transmission, 2020, 127, 311-322.	1.4	13
34	Migraine and tension-type headache triggers in a Greek population. Arquivos De Neuro-Psiquiatria, 2015, 73, 665-669.	0.3	12
35	Blink reflex habituation in migraine and chronic tension-type headache. Neurological Sciences, 2017, 38, 993-998.	0.9	12
36	Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. Journal of Parkinson's Disease, 2020, 10, 481-487.	1.5	12

ANASTASIA BOUGEA

#	Article	IF	CITATIONS
37	CADASIL and Autoimmunity: Coexistence in a Family with the R169C Mutation at Exon 4 of the <i>NOTCH3</i> Gene. Cerebrovascular Diseases, 2014, 38, 302-307.	0.8	11
38	Gastroesophageal reflux disease symptoms in the Greek general population: prevalence and risk factors. Clinical and Experimental Gastroenterology, 2016, 9, 143.	1.0	11
39	Synuclein in neurodegeneration. Advances in Clinical Chemistry, 2021, 103, 97-134.	1.8	10
40	Donepezil-Induced Myoclonus in a Patient With Alzheimer Disease. Annals of Pharmacotherapy, 2014, 48, 1659-1661.	0.9	9
41	Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. Epilepsy and Behavior, 2016, 55, 84-86.	0.9	9
42	In vivo Prevalence of Alzheimer Biomarkers in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2019, 47, 289-296.	0.7	9
43	Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism and Related Disorders, 2021, 84, 1-4.	1.1	9
44	A Systematic Review of Randomized Controlled Interventions for Parents' Distress in Pediatric Leukemia. ISRN Oncology, 2011, 2011, 1-6.	2.1	8
45	Thyroid Autoantibodies in the Cerebrospinal Fluid of Subjects with and without Thyroid Disease: Implications for Hashimoto's Encephalopathy. Journal of Thyroid Research, 2015, 2015, 1-4.	0.5	8
46	A Novel Machine Learning Algorithm Predicts Dementia With Lewy Bodies Versus Parkinson's Disease Dementia Based on Clinical and Neuropsychological Scores. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 317-320.	1.2	8
47	Impact of the apelin/APJ axis in the pathogenesis of Parkinson's disease with therapeutic potential. Journal of Neuroscience Research, 2021, 99, 2117-2133.	1.3	8
48	Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers. Parkinsonism and Related Disorders, 2021, 91, 1-8.	1.1	8
49	The multifaceted clinical presentation of VCP-proteinopathy in a Greek family. Acta Myologica, 2017, 36, 203-206.	1.5	8
50	Do heterozygous HTRA1 mutations carriers form a distinct clinical entity?. CNS Neuroscience and Therapeutics, 2018, 24, 1299-1300.	1.9	7
51	The Role of Allergy in Phonation. Journal of Voice, 2019, 33, 811.e19-811.e27.	0.6	7
52	Elevated Serum α-Synuclein Levels in Huntington's Disease Patients. Neuroscience, 2020, 431, 34-39.	1.1	7
53	REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers. Sleep, 2021, 44, .	0.6	6
54	MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review. Medicina (Lithuania), 2022, 58, 483.	0.8	6

#	Article	IF	CITATIONS
55	Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis. Revue Neurologique, 2014, 170, 228-229.	0.6	5
56	Multiple sclerosis and Parkinson's disease: the two faces of neurodegeneration. Report of the first Greek case and review of the literature. Neurological Sciences, 2015, 36, 2281-2285.	0.9	5
57	DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. Parkinsonism and Related Disorders, 2020, 77, 36-42.	1.1	5
58	Genotyping and Plasma/Cerebrospinal Fluid Profiling of a Cohort of Frontotemporal Dementia–Amyotrophic Lateral Sclerosis Patients. Brain Sciences, 2021, 11, 1239.	1.1	5
59	Primary headache subtypes and thyroid dysfunction: Is there any association?. Arquivos De Neuro-Psiquiatria, 2020, 78, 695-699.	0.3	5
60	Psychosis in Parkinson's Disease: A Lesson from Genetics. Genes, 2022, 13, 1099.	1.0	5
61	Capecitabine Induced Multifocal Leukoencephalopathy: Do We Have Always to Switch off the Chemotherapy?. Case Reports in Oncological Medicine, 2016, 2016, 1-3.	0.2	4
62	Serial MRI images of an unusual presentation of anti-GAD encephalitis: A new pattern?. Journal of Neuroradiology, 2017, 44, 167-169.	0.6	3
63	COVID-19 and Holy Communion. Public Health, 2020, 187, 134-135.	1.4	3
64	lf not salivary alpha-synuclein, then what? A look at potential Parkinson's disease biomarkers. Expert Review of Molecular Diagnostics, 2020, 20, 359-361.	1.5	3
65	Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study. Journal of Parkinson's Disease, 2021, 11, 633-640.	1.5	3
66	Understanding of headache patterns modification in an emergency department during the economic crisis of Greece. Neurological Sciences, 2016, 37, 1233-1239.	0.9	2
67	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoancepahlopathy presenting with postpartum psychosis and late-onset stroke. Future Neurology, 2016, 11, 207-213.	0.9	2
68	Vasculitis in the Central Nervous System. Advances in Experimental Medicine and Biology, 2017, 1003, 173-185.	0.8	2
69	Relación entre calidad de vida, sÃntomas psicopatológicos y formas de afrontamiento en las enfermeras griegas. EnfermerÃa ClÃnica, 2020, 30, 23-30.	0.1	2
70	CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes. Neurology: Clinical Practice, 2021, 11, e867-e875.	0.8	2
71	Job stress and burnout in the care staff of Leros PIKPA Asylum 25 years after the first Deinstitutionalisation and Rehabilitation Greek Project. BJPsych Bulletin, 2016, 40, 296-301.	0.7	1
72	Recognition of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) in Two Oligosymptomatic Sisters with Low CADASIL Scale Scores and a Venous Dysplasia: Report of a Novel Greek Family. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, e191-e195.	0.7	1

ANASTASIA BOUGEA

#	Article	IF	CITATIONS
73	Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?. Fundamental and Clinical Pharmacology, 2019, 33, 687-688.	1.0	1
74	A Critical Evaluation of the Studies Included in Brenes et al. 2019 on the Therapeutic Effects of Yoga in People With Dementia. American Journal of Geriatric Psychiatry, 2020, 28, 1224-1225.	0.6	1
75	P3â€209: Impact of Biomarkers On Diagnostic Confidence in Clinical Assessment of Patients with Suspected Alzheimer's Disease and High Diagnostic Uncertainty: An EADC Study. Alzheimer's and Dementia, 2016, 12, P904.	0.4	0
76	Novel PANK2 mutation in the first Greek compound heterozygote patient with pantothenate-kinase-associated neurodegeneration. SAGE Open Medical Case Reports, 2017, 5, 2050313X1772010.	0.2	0
77	An unusual phenocopy of the HANAC syndrome without genetic involvement of COL4A1/COL4A2. Acta Neurologica Belgica, 2018, 118, 135-136.	0.5	0
78	Relationship of quality of life, psychopathologic symptoms and ways of coping in Greek nursing staff. EnfermerÃa ClÃnica (English Edition), 2020, 30, 23-30.	0.1	0
79	An Update on the Less-known Group of Other Primary Headaches – A Review. European Neurological Review, 2014, 9, 71.	0.5	0
80	Headache Profile Change in an Emergency Department during the Economic Crisis of Greece. Journal of Neurology and Neurosurgery, 2015, 02, .	0.3	0
81	An Evaluation of the Studies on the Therapeutic Effects of Yoga in People with Dementia. European Medical Journal Neurology, 0, , 64-66.	0.0	0
82	Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. Parkinsonism and Related Disorders, 2022, 98, 72-74.	1.1	0